APIMEDS PHARMACEUTICALS US, INC. Investment Income, Interest
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Investment Income, Interest of $21.76 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. investment income, interest for the quarter ending 2026-06-30 was $21.76K, a 42.74% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. investment income, interest for the quarter ending 2026-03-31 was $7.00, a 133.33% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. investment income, interest for the quarter ending 2025-12-31 was $35.92K, a 119630.00% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. investment income, interest for the quarter ending 2025-09-30 was $56.43K, a 48543.10% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. investment income, interest for fiscal 2025 was $107.59K, a 3710.02% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. investment income, interest for fiscal 2024 was $2.82K, a 63.85% decline from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. investment income, interest for fiscal 2023 was $7.81K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.76K 10-Q · filed 2026-08-14 | $21.77K 10-Q · filed 2026-08-14 | $57.69K derived: sum of 3 quarters · filed 2026-08-14 | $114.12K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $7.00 10-Q · filed 2026-05-26 | $35.93K derived: sum of 2 quarters · filed 2026-05-26 | $92.35K derived: sum of 3 quarters · filed 2026-05-26 | $107.60K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $35.92K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $92.34K derived: sum of 2 quarters · filed 2026-05-04 | $107.59K derived: sum of 3 quarters · filed 2026-08-14 | $107.59K 10-K · filed 2026-05-04 |
| 2025-09-30 | $56.43K 10-Q · filed 2025-11-12 | $71.67K derived: sum of 2 quarters · filed 2026-08-14 | $71.68K 10-Q · filed 2025-11-12 | $71.71K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $15.25K 10-Q · filed 2026-08-14 | $15.25K 10-Q · filed 2026-08-14 | $15.28K derived: sum of 3 quarters · filed 2026-08-14 | $15.40K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $3.00 10-Q · filed 2026-05-26 | $33.00 derived: sum of 2 quarters · filed 2026-05-26 | $149.00 derived: sum of 3 quarters · filed 2026-05-26 | $666.00 derived: sum of 4 quarters · filed 2026-05-26 |
| 2024-12-31 | $30.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $146.00 derived: sum of 2 quarters · filed 2026-05-04 | $663.00 derived: sum of 3 quarters · filed 2026-05-04 | $2.82K 10-K · filed 2026-05-04 |
| 2024-09-30 | $116.00 10-Q · filed 2025-11-12 | $633.00 derived: sum of 2 quarters · filed 2025-11-12 | $2.79K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $517.00 10-Q · filed 2025-08-19 | $2.68K 10-Q · filed 2025-08-19 | ||
| 2024-03-31 | $2.16K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $7.81K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |